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Background and purpose: Palliative radiotherapy is given to sustain or improve quality of life for patients
with advanced cancer. Radiotherapy may however result in symptomatic side effects, which may affect
the patient negatively. This prospective longitudinal study of 30 patients aimed at investigating the inci-
dence and severity of early toxicity, particularly focusing on dysphagia, esophagitis and mucositis, follow-
ing fractionated radiotherapy for cervical and thoracic metastatic spinal cord compression (MSCC), as
well as determining the relationship between esophageal dose and early upper gastro-intestinal symp-
toms.
Materials and methods: Thirty patients receiving radiotherapy of 3Gyx10 for MSCC were included in the
study. Patients were assessed for a total of 7 weeks from onset of radiotherapy using the Edmonton
Symptom Assessment System (ESAS) questionnaire. Upper gastro-intestinal symptoms and severity were
assessed from the tenth and eleventh question section of the ESAS questionnaire of ‘‘other problems” and
how much this affected them. The relationships between the mean and maximum esophageal doses and
incidence of dysphagia, esophagitis or mucositis were estimated and dose response curves determined.
Results: Eleven patients reported esophageal symptoms (average duration eleven days, range 1–18 days).
Incidence of esophageal toxicity in patients treated at Th8 or above was 79 percent, while no patients
treated below Th8 reported any symptoms (p < 0.001). Furthermore, 2 out of 3 patients irradiated at
the cervical region reported substantial changes in taste sensation.
Risk of symptoms correlated with both mean and maximum esophageal dose and may be a useful tool
in planning radiotherapy for MSCC, potentially reducing early upper gastro-intestinal toxicity.
 2019 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy &
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Five to ten percent of cancer patients experience symptomatic
compression of the spinal cord or the cauda equina frommetastatic
disease (metastatic spinal cord compression, MSCC) [1]. Symptoms
of MSCC include severe neuropathic pain and other neurological
symptoms including motor dysfunction and weakness, numbness
and bladder or bowel dysfunction [2]. It is a disabling complication,
which untreated will further the complication of these symptomsand may lead to paralysis, loss of medullar function distally from
the compression and incontinence [3,4].
Life expectancy is typically short at the time of MSCC diagnosis,
with a 1-year survival rate of 30% [5]. Interventions for MSCC
mainly aim at improving quality of life (QoL), through pain control
and by maintaining or improving functional capacity.
Early detection and rapid onset of treatment are key elements
for improved outcomes. Pre-treatment ambulatory function and
time of developing motor symptoms are the primary predictors
of post-treatment functional outcomes [6]. Thus, patients with
lower-extremity function and sensation at the onset of treatment
have better prognosis for maintaining their functional indepen-
dence and longer survival time [7].
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teroids and radiotherapy (RT), or a combination of these, with RT
being one of the key treatment modalities offered for MSCC [2].
Patients may, however, experience early toxicity from the RT,
which paradoxically may affect their well-being and contribute
to a decline in their QoL. Previous studies investigating adverse
effects found early toxicity related to RT for MSCC to include
gastro-intestinal toxicity, mucositis, bone-marrow suppression,
and myelopathy, depending on the level of the irradiated spine
[1,8]. However, none of these studies have systematically and
specifically investigated early toxicity related to incidental irradia-
tion of the esophagus.
Mucositis is a known side effect of radiotherapy in head and neck
cancers [9]. When investigating radiotherapy-related toxicity, the
focus is often on toxicity of the Common Terminology Criteria for
Adverse Events grade 3 or above. However, due to the short life
expectancy [3] and the primary QoL-focused treatment intent for
these palliative patients, it is highly relevant to investigate milder
toxicity as well. Milder toxicity might still have significant impact
on the patient’s well-being, and particularly mucositis in the
gastro-intestinal tract could be unappreciated and underreported.
This is supported by anecdotal reports from patients having previ-
ouslybeen irradiated forMSCCat the level of the esophagus. The tox-
icity of the treatment may be measured using various approaches;
oneof themostpreferredmethods is patient reportedoutcomemea-
sures [10]. This allows patients to report self-experienced symp-
toms, providing a patient-focused perspective of adverse events.
In this prospective longitudinal study, we aimed at investigating
the patient-reported incidence and severity of symptoms, particu-
larly focusing on dysphagia, esophagitis and mucositis following
fractionated RT for MSCC, and its relationship with dose to the
esophagus.Materials & methods
This prospective study included 30 consecutively treated
patients with advanced cancer receiving fractionated RT for MSCC
at the Department of Oncology, Rigshospitalet, Denmark. Patients
with a minimum life expectancy of 6 months were eligible for
the study if they were prescribed moderately hypo-fractionated
radiotherapy (30 Gy in 10 fractions) for MSCC, which is local hos-
pital standard for patients with a life expectancy of 6 months or
above to ensure tumor control, and had not previously received
irradiation to the site in question [2,11]. General performance sta-
tus was based on the ECOG performance status and life expectancy
was based on the Tokuhashi score [12]. The target was defined as
the entire involved vertebrae including the relevant spinous pro-
cesses, with a 5 mm planning target volume (PTV) margin. For
organs at risk (OARs), arms, kidneys and small bowel for caudal
target volumes were outlined as part of the treatment planning
process, as well as the spinal cord to avoid hotspots within the
spinal cord. For arms the maximum dose (Dmax) was 3 Gy and as
low as possible for other OARs. Currently there are no local hospital
recommendations for OAR delineation of the esophagus or lungs
for MSCC prior to treatment planning. The entire esophagus, from
the cricoid to the gastro-esophageal junction was retrospectively
delineated for all patients [13].
Patients were planned with the EclipseTM planning system (Var-
ian Medical Systems, Palo Alto, CA, USA) calculated using Acuros
XB (version 13.6) and subsequently treated with simple single
arc volumetric modulated arc therapy (VMAT). Multiple targets
per patient were also allowed. Patients were treated five days a
week with daily cone beam computed tomography (CBCT) image
guidance.Assessment
The Edmonton Symptom Assessment System (ESAS) is devel-
oped to screen nine symptoms in patients with advanced cancer
on numerical scales (NRS)(scale 0–10). In the ESAS, patients rate
the severity of the following nine symptoms: pain, activity, nausea,
depression, anxiety, drowsiness, lack of appetite, well-being, and
shortness of breath on a 10-cm line. The sum of patient responses
to these nine symptoms is the ESAS distress score. Further, the
questionnaire adds an optional tenth symptom, which can be
added by the patient. This tenth symptom allows for the opportu-
nity for patients to add an additional symptom, which clinicians
may not have considered. The ESAS has well-established reliability
and validity as a routine self-assessment tool in patients with
advanced cancer [14].
On the first day of treatment, baseline data were acquired prior
to RT delivery. Patients filled in the ESAS questionnaire and their
answers were recorded by a radiation therapy technologist or radi-
ation therapy nurse at the clinic for the initial 3 weeks and weekly
for the remaining 4 weeks. Thus, patients were followed for
7 weeks in total, or until they either could no longer cooperate or
decided to leave the study.
Patients reported their symptoms according to ESAS to
an RT technologist or RT nurse. Further, patients were interviewed
either in the clinic, after each RT fraction, or by phone post-
treatment.
The incidence of dysphagia, esophagitis and/or mucositis was
determined from the patient responses on the optional tenth
symptom in the ESAS titled ‘‘Other problem”, where patients were
asked if they experienced any symptoms not mentioned in the
above questions”, where patients were given the opportunity to
self-report any adverse effects. Since early toxicity typically
emerged after the first week following RT, patients who were not
followed for at least 7 days were excluded from the current analy-
sis. Any level of dysphagia, esophagitis and/or mucositis was
recorded, irrespective of severity. The severity of the early toxicity
was estimated based on the question following the tenth optional
symptom in the ESAS questionnaire: ‘‘How much does this affect
you?”. The severity was based on a scale of 0–10, where 0 was
not affected and 10 was worst imaginable. The patient’s reported
answers were collected.
Ethics
Approval was obtained from the regional research ethics com-
mittee (Reg. no. 49984) and the Danish data protection agency,
and all patients provided oral and written informed consent for
study participation.
Statistics
Basic descriptive statistics were used to report patient charac-
teristics, and incidence and average duration of early toxicity were
established based om patient self-report.
The severity of the early toxicity was recorded as the highest
patient self-reported score, based on the patient’s self-reporting
of how much the toxicity affected them and an average value
was calculated.
The incidence of dysphagia, esophagitis or mucositis in patients
with at least one treated vertebra at Th8 or above was compared to
the incidence for patients treated below Th8 only, using Fisher’s
exact test. The relationship between the mean (Dmean) and Dmax
esophageal doses and incidence of dysphagia, esophagitis or
mucositis were examined using the Wilcoxon rank sum test, com-
paring distributions of dose metrics in the two groups. Dose-
response curves for the mean and maximum esophagus doses were
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used as level of significance.Fig. 1. Overview of patient-reported dysphagia, esophagitis or mucositis in the days
following RT for MSCC, represented in order of when toxicity was reported. The
days where the patients reported toxicity of the gastro-intestinal tract are indicated
with solid black circles d. The patients are represented in order of first experienced
toxicity (not study enrolment). End of follow-up is marked with a star :.
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Thirty patients (12 women / 18 men) participated in the study.
Four patients were excluded from this analysis due to change in
fractionation (one patient) or inability to complete questionnaires
beyond the week one assessment (three patients). Patient charac-
teristics can be viewed in Table 1.
Out of the 26 patients, 11 reported treatment-related toxicity of
the gastrointestinal tract (Fig. 1); the average duration of the
adverse symptoms was 11 days (range 1–18 days). All patients
reporting dysphagia, esophagitis or mucositis were treated at Th8
or above 11/14 (79%); while no patients treated below Th8
reported any symptoms (0/12, p < 0.001). Furthermore, 2 out of 3
patients irradiated at the cervical region reported substantial
changes in taste sensation. Out of the 11 patients reporting early
toxicity of the upper gastro-intestinal tract, 10 patients rated the
severity. The average rating of how much the toxicity affected
the patients was 4.4 (range 2–7) (Fig. 2).
The median Dmean was 7.7 Gy (range 0.1–15.9 Gy) for patients
reporting dysphagia, esophagitis and/or mucositis, and 0.2 Gy
(0.0–10.8 Gy) for patients not reporting these toxicities, respec-
tively (p = 0.004). Corresponding values for Dmax were 30.4 Gy
(1.1–31.3 Gy) for those reporting dysphagia, esophagitis or
mucositis and 0.5 Gy (0.0–31.4 Gy) for those without these toxici-
ties, respectively (p = 0.009).
Dose response curves, as estimated using univariate logistic
regression, for mean and maximum dose to the esophagus are
shown in Fig. 3; with summary data points added for illustration
of model fit. A change in mean dose of 1 Gy corresponded to an
estimated odds ratio (OR) for developing toxicity of the gastro-
intestinal tract of 1.38 (95% confidence interval 1.09–1.76). OR
for a change in maximum dose of 1 Gy was 1.11 (1.03–1.20).0 1 2 3 4 5 6 7 8 9 10
Patient
0
Fig. 2. Shows the patients‘ self-evaluation of how dysphagia, esophagitis or
mucositis affected them on a scale of 0–10, where 0 is not affected and 10 is
highest possible. Patients‘ self-evaluation ranged from 2-7, with a mean value of 4,
4. 10 out of 11 patients reporting upper gastro-intestinal symptoms reported the
severity of these symptoms. Patients are represented in the order of first
experienced symptoms.Discussion
This prospective longitudinal study aimed at investigating the
patient-reported incidence and severity of symptoms, following
fractionated RT for MSCC, and its relationship with dose to the
esophagus.
In this prospective consecutive study of early toxicity for
patients receiving RT for MSCC, we observed a high incidence of
dysphagia, esophagitis and mucositis, and a strong correlation
between treatment site and occurrence of this RT-related toxicity.Table 1
Patient characteristics of the 26 patients included in the final analysis.
Median Range
Age (y) 65 39–84
Treated vertebra (n) 2 1–9
n %
Sex
Male 15 58
Female 11 42
Primary disease
Prostate 6 23.1
Breast 4 15.4
Gynecological 3 11.5
Lung 2 7.7
Esophagus 2 7.7
Unknown primary tumor 2 7.7
Gastroesophageal junction 2 7.7
Neuroendocrine tumor 2 7.7
Other 3 11.5Previous studies investigating adverse effects and toxicity
of RT have not focused mainly on the acute toxicity, but on the
treatment efficacy in comparing treatments or treatment regimens
[1,8,15,16]. Fractionation schemes and reporting methods, out-
comes, as well as patient follow-up vary considerably between
studies, which can make comparison of toxicity reporting difficult.
In contrast to previous studies, which typically have measured
toxicity  grade 3, this study included any type and severity of
patient reported symptoms. This may be a contributing factor to
the high incidence of symptom reporting in this study. However,
as these patients have a short remaining life span and the intent
of RT for MSCC is to improve QoL through pain control and by
maintaining or improving of functional capacity, we find it highly
relevant to investigate any toxicity, which may have a physical
or psychological effect on the patient’s well-being.
In a report on 1304 MSCC patients, Rades et al found only grade
1 early toxicity and no late toxicity [1]. In a study of 149 patients
treated stereotactically, Wang et al reported the following grade
3 toxicities: dysphagia (one), neck pain (one), pain associated with
severe tongue edema and trismus (two) [15]. In another study of
Fig. 3. The risk of toxicity of the gastro-intestinal tract as a function of mean and maximum esophageal dose, as estimated using univariate logistic regression. Model
coefficients were b0 = 1.953 (95% CI 3.534 – 0.371), bmean = 0.324 (0.085 – 0.564) and b0 = 2.414 (4.522 – 0.307), bmean = 0.106 (0.026 – 0.186) for the estimates of mean
and max dose, respectively. Data points with 95% confidence intervals are added for illustration only, and represent all patients separated into 3 bins.
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above grade 1 using the National Cancer Institute Common Toxic-
ity Criteria, and no late toxicity [16]. In a study of 276 patients,
Maranzano et al found very few cases of grade 3 esophagitis or
laryngitis (1,5% of the patients) [8]. Unlike our study, patient
follow-up in these studies occurred at varying time points, typi-
cally with months apart. Rades et al assessed the patients prior
to initiation of RT, as well as 1, 3 and 6 months after RT [1]. Wang
et al measured baseline as well as 3 and 6 months after RT [15].
Maranzano followed the patients ‘‘before and after RT”, and once
monthly [8]. In this study we used the ESAS questionnaire as a val-
idated questionnaire in patients with cancer for symptoms screen-
ing. This was chosen due to palliative intent of treatment in
patients with advanced cancer. Other questionnaires have been
used in different settings depending on the context of treatment.
A PRO questionnaire does not access causality of symptoms but
throughout objective assessment by physician during and after
treatment would be burdensome and require additional clinical
visit. The PRO-CTCAE has been used to access similar symptoms
of dysphagia in patients undergoing chemoradiotherapy for head
& neck cancer. This study found a disagreement of symptoms
reported by patient with lower severity reported by physician
assessment [17]. Such a disagreement also exists comparing the
symptoms reported in current study with a low incidence of treat-
ment related symptoms in the studies mentioned above.
Generally, symptomatic gastro-intestinal toxicity in our study
was first observed about one week after initiation of RT and had
a typical duration of 1–2 weeks (median duration 11 days).
Because early toxicity, as shown in our results, may be of short
duration, and because patients may not report a transient toxicity
at follow-up sessions occurring 1, 3 and 6 months after RT, the inci-
dence of oral and esophageal toxicity may have been underesti-
mated in the literature.
Additionally, some patients reporting symptoms in this study
considered these not to be toxicity related symptoms, but due to
tumor growth, which in a couple of patients in this study created
additional and unnecessary anxiety, depression and grief for them-
selves and their families. The causes of the symptoms were
explained and resolved during follow-up sessions in our study;
however, this misconception may likely add to the under-
reporting of toxicity symptoms.
In contrast to previous studies, we found that gastro-intestinal
toxicity following palliative RT for MSCC may occur in a substantial
proportion of patients for whom the target is situated at the level
of the esophagus. This study showed no patients experiencing
symptoms below the level of TH8, which typically is situated just
above the gastro-intestinal junction. Due to the surprising resultsof this optional tenth point in the ESAS questionnaire, further
enquiries about the experienced upper gastro-intestinal symptoms
of these patients were not made systematically. However, further
investigations to clarify these symptoms, duration and severity in
a larger population should be conducted.
In order to support this patient group in dealing with these
potential toxicities, we suggest that patients undergoing RT for
MSCC at the level of the upper or central part of the thoracic spine
or above should be timely informed that they can expect to expe-
rience gastro-intestinal toxicity as well as a change in taste sensa-
tion, which likely will last up to 3 weeks. This may help to reduce
worries and anxiety for the patients, as well as give them a better
base of informed consent for this treatment. Several patients in this
study reported not to have been properly informed about these
potential toxicities pre-treatment. This study, however, bases on
a small patient group and further studies regarding patient
reported esophageal toxicity should be performed to further verify
and clarify these findings and their clinical significance for the
patient-reported outcomes.
Furthermore, if the RT is delivered using VMAT, it may be pos-
sible to optimize treatment plans to reduce dose to the esophagus
and oral cavity. Our limited data indicate that there may exist a
dose–response relationship for gastro-intestinal toxicity of the
esophagus and oral cavity, justifying a rationale for further dose
plan optimization.
Finally, it should be noted that these patients underwent a frac-
tionation scheme of 30 Gy in 10 fractions. The optimal fractiona-
tion schedule for this patient population is still under debate and
toxicities may vary in this patient group depending on the chosen
fractionation scheme.
In conclusion, in this prospective study of 30 patients, 79% of
patients who received RT for MSCC for the cervical and upper tho-
racic spinal column experienced toxicity of the gastro-intestinal
tract. All patients stated that this toxicity affected them. This pre-
liminary data is contrasting previously published findings, most
likely due to the inclusion of all types and intensity levels of toxi-
city, as well as a much earlier and more frequent follow-up assess-
ments compared to former studies. A dose-response relationship
for RT of the esophagus may exist and could be a useful tool in
planning of RT for MSCC, potentially reducing the incidence of tox-
icity of the gastro-intestinal tract.
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